TY - JOUR
T1 - Use of venoactive drugs after surgery for varicose veins
T2 - A preliminary study
AU - Mazzaccaro, Daniela
AU - Muzzarelli, Lorenzo
AU - Modafferi, Alfredo
AU - Righini, Paolo C.
AU - Settembrini, Alberto M.
AU - Nano, Giovanni
PY - 2018/2/1
Y1 - 2018/2/1
N2 - BACKGROUND: The aim of this paper was to assess the use of venoactive drugs (VADs) after surgery for chronic venous disease in our operative unit in terms of patients' compliance to the therapy and a possible effect on the postoperative pain and quality of life (QoL). METHODS: Data of consecutive patients who underwent surgery were retrospectively analyzed. All patients, through telephone interview 90 days after the operation, were asked about taking the VAD (either sulodexide or MPFF) which was recommended during the postoperative period. Data were collected about the duration of therapy, the intensity of perceived pain (0-10 scale) at 1st, 7th and 30th postoperative days (POD), the length of rest from their daily activities and QoL during the first postoperative month (through Italian SF-12 questionnaire). P values < 0.05 were considered significant. Results of patients who took the VAD were compared to those of patients who did not take the VAD (case-controlled study). RESULTS: A total of 132 patients were operated on (43 with endovenous radiofrequency ablation, RFA; 43 with stripping or crossectomy; 46 with phlebectomies). The proportion of patients who took VADs was two thirds, similar among the three groups. Of those, 24% took VADs for less than 30 days. No significant differences were recorded between those who took and those who didn't take any drugs in terms of intensity of pain at 1st, 7th and 30th POD, days of rest from daily activities and QoL. CONCLUSIONS: Irrespectively of the groups, about one third of the patients did not take the recommended VAD postoperatively. No significant difference was recorded between those who took the therapy and those who did not in terms of intensity of postoperative pain, length of rest from daily activities and QoL.
AB - BACKGROUND: The aim of this paper was to assess the use of venoactive drugs (VADs) after surgery for chronic venous disease in our operative unit in terms of patients' compliance to the therapy and a possible effect on the postoperative pain and quality of life (QoL). METHODS: Data of consecutive patients who underwent surgery were retrospectively analyzed. All patients, through telephone interview 90 days after the operation, were asked about taking the VAD (either sulodexide or MPFF) which was recommended during the postoperative period. Data were collected about the duration of therapy, the intensity of perceived pain (0-10 scale) at 1st, 7th and 30th postoperative days (POD), the length of rest from their daily activities and QoL during the first postoperative month (through Italian SF-12 questionnaire). P values < 0.05 were considered significant. Results of patients who took the VAD were compared to those of patients who did not take the VAD (case-controlled study). RESULTS: A total of 132 patients were operated on (43 with endovenous radiofrequency ablation, RFA; 43 with stripping or crossectomy; 46 with phlebectomies). The proportion of patients who took VADs was two thirds, similar among the three groups. Of those, 24% took VADs for less than 30 days. No significant differences were recorded between those who took and those who didn't take any drugs in terms of intensity of pain at 1st, 7th and 30th POD, days of rest from daily activities and QoL. CONCLUSIONS: Irrespectively of the groups, about one third of the patients did not take the recommended VAD postoperatively. No significant difference was recorded between those who took the therapy and those who did not in terms of intensity of postoperative pain, length of rest from daily activities and QoL.
KW - Quality of life
KW - Therapeutics
KW - Varicose veins
UR - http://www.scopus.com/inward/record.url?scp=85040921676&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85040921676&partnerID=8YFLogxK
U2 - 10.23736/S0392-9590.17.03875-5
DO - 10.23736/S0392-9590.17.03875-5
M3 - Article
C2 - 28976172
AN - SCOPUS:85040921676
SN - 0392-9590
VL - 37
SP - 79
EP - 84
JO - International Angiology
JF - International Angiology
IS - 1
ER -